Login to Your Account

Financings Roundup

Chimerix Raises $45M for Antiviral Development

By Catherine Shaffer

Tuesday, February 15, 2011
A new infusion of $45 million will help Chimerix Inc. advance the development of clinical-stage antiviral candidates that target a number of viruses. CMX001 is in clinical trials for cytomegalovirus and adenovirus with potential for use as a smallpox countermeasure.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription